Remimazolam: First Approval

被引：150
作者：
Keam, Susan J. [1 ]
机构：
[1] Springer Nat, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS | 2020年 / 80卷 / 06期
关键词：
CNS; 7056; MIDAZOLAM; SAFETY; EFFICACY; PLACEBO; PHARMACODYNAMICS; PHARMACOKINETICS; SEDATION;
D O I：
10.1007/s40265-020-01299-8
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Remimazolam (Anerem(R) in Japan; ByFavo (TM) in the USA; Aptimyda (TM) in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.
引用
收藏
页码：625 / 633
页数：9
相关论文
共 25 条
  • [1] A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics
    Antonik, Laurie J.
    Goldwater, D. Ronald
    Kilpatrick, Gavin J.
    Tilbrook, Gary S.
    Borkett, Keith M.
    [J]. ANESTHESIA AND ANALGESIA, 2012, 115 (02) : 274 - 283
  • [2] Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents
    Bevans, Tatjana
    Deering-Rice, Cassandra
    Stockmann, Chris
    Rower, Joseph
    Sakata, Derek
    Reilly, Christopher
    [J]. ANESTHESIA AND ANALGESIA, 2017, 124 (05) : 1484 - 1490
  • [3] A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy
    Borkett, Keith M.
    Riff, Dennis S.
    Schwartz, Howard I.
    Winkle, Peter J.
    Pambianco, Daniel J.
    Lees, James P.
    Wilhelm-Ogunbiyi, Karin
    [J]. ANESTHESIA AND ANALGESIA, 2015, 120 (04) : 771 - 780
  • [4] ClinicalTrials.gov, 2015, SAF EFF REM ASA 3 4
  • [5] Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers Part II. Pharmacodynamics of Electroencephalogram Effects
    Eisenried, Andreas
    Schuettler, Juergen
    Lerch, Marco
    Ihmsen, Harald
    Jeleazcov, Christian
    [J]. ANESTHESIOLOGY, 2020, 132 (04) : 652 - 666
  • [6] EU Clinical Trials Register, 2016, RAND SINGL BLIND PHA
  • [7] Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system
    Freyer, Nora
    Knoespel, Fanny
    Damm, Georg
    Greuel, Selina
    Schneider, Christin
    Seehofer, Daniel
    Stoehr, Thomas
    Petersen, Karl-Uwe
    Zeilinger, Katrin
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1033 - 1047
  • [8] Google Patents, 2020, DOS REG SED CNS 7056
  • [9] Hill N, 2019, AM J RESP CRIT CARE, V199
  • [10] CNS 7056 - A novel ultra-short-acting benzodiazepine
    Kilpatrick, Gavin J.
    McIntyre, Margaret S.
    Cox, Richard F.
    Stafford, Jeffrey A.
    Pacofsky, Gregory J.
    Lovell, Gwyer G.
    Wiard, Robert P.
    Feldman, Paul L.
    Collins, Holly
    Waszczak, Barbara L.
    Tilbrook, Gary S.
    [J]. ANESTHESIOLOGY, 2007, 107 (01) : 60 - 66
123